Who is sponsoring NCT00148928?

NCT00148928 is sponsored by GlaxoSmithKline.

What condition does NCT00148928 study?

NCT00148928 studies Neoplasms, Prostate.

What drugs are being tested in NCT00148928?

Interventions: P501-AS15 vaccine.

What is the status of NCT00148928?

NCT00148928 is currently COMPLETED.

Last reviewed 2017-06-02 · How we verify

Safety & Activity of P501-AS15 Vaccine as a First-line Treatment for Patients With Hormone-sensitive Prostate Cancer Who Show Rising PSA

NCT00148928 PHASE1 COMPLETED

Patients with hormone-sensitive prostate cancer and rising PSA, after primary tumor treatment, will be treated with the P501-AS15 vaccine as out-patients. The maximum dose will be 16 vaccinations, given over a period of approximately one year. Thereafter, the patients' long-term safety and PSA status will be followed over a period of approximately 11 months.

Details

Lead sponsor	GlaxoSmithKline
Phase	PHASE1
Status	COMPLETED
Enrolment	25
Start date	Tue Mar 01 2005 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Tue Nov 07 2006 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Neoplasms, Prostate

Interventions

P501-AS15 vaccine

Countries

Belgium, France